MetaCap

Mentari Therapeutics (MTRI) vs Savara (SVRA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Savara is the larger company by market cap ($939.9 million vs $856.9 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MTRI+0.68%SVRA-20.67%
+39%+7%-24%
Aug 17, 20261 yearNov 20, 2026
MTRI+0.68%SVRA-23.79%
+30%+1%-27%
Aug 17, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MTRI versus SVRA key metrics
MetricMTRISVRA
Share price$14.70$4.26
Market cap$856.94M$939.86M
1-day change-3.57%-18.23%
YTD return—-29.35%
1-year return—-13.41%
5-year return—+270.43%
EPS (TTM)—$-0.60
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-118.84M
52-week high$23.30$7.01
52-week low$5.75$4.00
Distance from 52-week high-36.91%-39.19%
Analyst consensusstrong_buystrong_buy
Avg. price target upside—+159.62%
Average volume19.42K2.79M
Shares outstanding58.30M220.62M
Employees—70
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Mentari Therapeutics

MTRI stock →

Mentari Therapeutics, Inc., a biotechnology company, develops and provides therapies for migraine prevention. The company's products include MT-001, an anti-PACAP monoclonal antibody designed for convenient subcutaneous dosing; MT-002, an anti-CGRP; and anti-PACAP bispecific antibody designed to inhibit these complementary pathways.

Health Care · Biotechnology: Pharmaceutical Preparations

About Savara

SVRA stock →

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 70 employees

MTRI vs SVRA FAQ

Which is bigger, Mentari Therapeutics or Savara?

Savara (SVRA) is larger, with a market capitalization of $939.86M compared with $856.94M for Mentari Therapeutics (MTRI).

Are Mentari Therapeutics and Savara in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons